1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Cystic Fibrosis Therapeutics Market (By Major Marketed Products, Pharmacological Class, & Geography) and Pipeline Analysis – Global Forecast to 2024

Cystic Fibrosis Therapeutics Market (By Major Marketed Products, Pharmacological Class, & Geography) and Pipeline Analysis – Global Forecast to 2024

  • October 2017
  • 121 pages
  • ID: 5139477
  • Format: PDF
  • By Igate Research

Summary

Table of Contents

Search Inside

The market for Cystic Fibrosis Therapeutics is anticipated to grow with double digit CAGR during the forecasting period. Cystic fibrosis is among the most common life-threatening genetic disorders worldwide. It is caused by defects in a single gene known as the cystic fibrosis transmembrane conductance regulator, or CFTR.

The increasing prevalence of cystic fibrosis, rising awareness about cystic fibrosis therapy, strong pipeline candidates, technological advancement and high rate of R&D initiatives are some of the major factors that are driving cystic fibrosis therapeutics market. However, high cost involved in treatment, increase in complexity of disease are restraining the cystic fibrosis therapeutics market.

Key Highlights of the Report
• United States dominates the global market for cystic fibrosis therapeutics.
• The EU5 countries together accounted for over 20% share of the global cystic fibrosis market in 2016.
• In Asian region, the prevalence of Cystic Fibrosis is observed to be very low in countries like China, India and Japan.
• On the basis of pharmacological class, the CFTR modulator captures highest share of the total CF therapeutics market in 2016.
• In 2016, mucolyctics agents accounted for around xx% of the global cystic fibrosis therapeutics market.
• Cystic Fibrosis patients who have reduced the levels of digestive enzymes due to improper functioning of pancreas, are treated by PERT to replace these enzymes.
• In 20XX, TOBI Podhaler generated sales worth US$ 300 Million.
• Italy has followed Ireland and other EU countries such as Germany, Austria, Denmark and Luxembourg in approving Orkambi for patients with CF.
• It’s estimated that 1 in every 2,500 babies born in the UK has cystic fibrosis.
• The revenues for Creon increased 22 percent in 2015, driven primarily by continued market growth.
• Zenpep sales surpassed US$ 200 Million mark in 2016.
• Some of the drugs that are under clinical studies are Tezacaftor (VX-661) + ivacaftor, VX-445 + tezacaftor + ivacaftor, VX-659 + tezacaftor + ivacaftor, PTI-428, AZD5634, QR-010 and POL6014 among many others.

iGATE RESEARCH report titled “Cystic Fibrosis Therapeutics Market (By Major Marketed Products, Pharmacological Class, & Geography) and Pipeline Analysis – Global Forecast to 2024” provides a comprehensive assessment of the Cystic Fibrosis Therapeutics Market.

This 121 Page report with 53 Figures and 6 Tables has been studied from 8 View Points:
1. Global Cystic Fibrosis Therapeutics Market & Forecast (2014 – 2024)
2. Global Cystic Fibrosis Therapeutics Market - Major Marketed Products Sales & Forecast (2012 - 2024)
3. Global Cystic Fibrosis Therapeutics Market - Pharmacological Class Sales & Forecast (2015 – 2021)
4. By Geography - Cystic Fibrosis Therapeutics Market (2014 – 2024)
5. Global Cystic Fibrosis Pipeline Product Analysis – By Company & Phase of Development
6. Cystic Fibrosis Company Profiles, Approved & Pipeline Product Analysis
7. Global Cystic Fibrosis Market - Industry Trends & Developments
8. Global Cystic Fibrosis Market - Growth Drivers & Challenges

Global Cystic Fibrosis Therapeutics Market - Major Marketed Products Covered
1. Orkambi (Lumacaftor/Ivacaftor)
2. Kalydeco (Ivacaftor)
3. Cayston (Inhaled Aztreonam)
4. Pulmozyme (Dornase Alfa)
5. TOBI/ TOBI Podhaler
6. Creon
7. Zenpep
8. Ventolin
9. Bronchitol (Inhaled Mannitol)
10. ADEKplusTM
11. Ibuprofen

Global Cystic Fibrosis Therapeutics Market - Pharmacological Class
• CFTR Modulators
• Mucolytic Agents
• Pancreatic Enzyme Replacement Products
• Antibiotics
• Other Therapies

Cystic Fibrosis Therapeutics Market – Geographical Analysis
1. United States
2. Canada
3. France
4. Germany
5. Italy
6. Spain
7. United Kingdom
8. Australia
9. Japan
10. China
11. India
12. South Korea

Cystic Fibrosis Company Profiles, Approved & Pipeline Product Analysis
1. Genentech, Inc. (A Member of the Roche Group)
2. Novartis
3. Gilead Sciences, Inc.
4. Vertex Pharmaceuticals Incorporated
5. AbbVie
6. GlaxoSmithKline
7. Johnson & Johnson
8. Allergan plc
9. Pharmaxis Ltd
10. Mylan N.V

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Neutrophil Elastase - Pipeline Review, H2 2019

  • $ 3500
  • December 2019
  • 65 pages

Neutrophil Elastase - Pipeline Review, H2 2019SummaryAccording to the recently published report ’Neutrophil Elastase - Pipeline Review, H2 2019’; Neutrophil Elastase (Bone Marrow Serine Protease o ...


ref:plp2017

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on